JPRN-UMIN000004715已完成2 期
A randomized phase 2 study of Docetaxel with or without Bevacizumab after platinum-based chemotherapy plus bevacizumab in patients with advanced non-squamous non-small-cell lung cancer - A randomized phase 2 study of Docetaxel with or without Bevacizumab after platinum-based chemotherapy plus bevacizumab in patients with advanced non-squamous non-small-cell lung cancer
适应症
试验速览
- 阶段
- 2 期
- 状态
- 已完成
- 入组人数
- 100
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional
入排标准
- 年龄范围
- 20years-old 至 ot applicable（—）
- 性别
- All
入选标准
- 未提供
排除标准
- •1) Prior treatment with docetaxel 2) Have central nervous system metastases (A patient who has previously treated brain metastases, without evidence of progression or hemorrhage at baseline is eligible) 3) Currently have or have a history of hemoptysis (>= one-half teaspoon of bright red blood per event) 4) Clinically significant drug allergy 5) Have a evidence of thrombosis 6) Have a serious concomitant active infection, which needs antibiotics, antimycotic drugs or virucide 7) Have a history of serious systemic disease including: clinically significant cardiovascular disease; medically uncontrolled diabetes and hypertension; gastrointestinal perforation, gastroparesis, or obstruction 8) Uncontrolled effusion (Pleural, peritoneal effusion, or cardiac effusion which requires drainage for symptom management) Regarding the patient who have or have had pleural effusion; a) A patients who developed recurrent effusion within two weeks after drainage tube removal is ineligible b) A patient who received intrapleural chemotherapy (excluding BRM such as OK432) for pleurodesis is ineligible 9) Patients with or with anticipation of invasive procedures as defined below: a) Major surgery within four weeks of registration b) Palliative radiotherapy within two weeks of registration c) Minor surgical procedures, core biopsy or traumatic injury, within two weeks of registration d) Transfusion of any blood products within two weeks of registration 10) Have another active malignancy 11) Interstitial pneumonia or pulmonary fibrosis documented obviously in chest X ray 12) Mental disease or psychotic manifestation 13) Pregnant or beeast-feeding woman or patient who doesn't agree to contraception 14) Not suitable for participating in the study for any other reason
研究者
相似试验
已完成
2 期
Randomized Phase II Study of Docetaxel (T) with or without Capecitabine (X) as Neoadjuvant Chemotherapy in Female Patients with Operable Breast Cancer Who were not Observed Disease Progression after 4 cycles of 5-Fluorouracil, Epirubicin and Cyclophosphamide (FEC) (OOTR N003)JPRN-C000000322Organization for Oncology and Translational Research (OOTR)500
已完成
2 期
Randomised Phase II study of combined Docetaxel and Nedaplatin versus Docetaxel alone chemotherapy in advanced or recurrent esophageal cancerAdvanced or recurrent esophageal cancerJPRN-UMIN000005877Toho University43
已完成
不适用
Randomized Phase II Trial Comparing Docetaxel with weekly Paclitaxel and Carboplatin in Elderly Patients with Non-Small Cell Lung CancerJPRN-UMIN000002616Tohoku University Hospital80
已完成
2 期
A Randomized phase II study of docetaxel versus weekly carboplatin and CPT-11 for previously treated Non-Small cell lung cancerJPRN-C000000147West Japan Oncology Group64
进行中（未招募）
1 期
A randomised phase II/III study of Docetaxel plus Prednisolone vs. Docetaxel plus Prednisolone plus Zoledronic acid vs. Docetaxel plus Prednisolone plus Strontium-89 vs. Docetaxel plus Prednisolone plus Zoledronic Acid plus Strontium-89 in Hormone Refractory Prostate Cancer metastatic to bone. - TRAPEZE: phase II/III efficacy and safety clinical trial in Hormone Refractory Prostate CancerHormone refractory Prostate Cancer (HRPC)EUCTR2004-002295-41-GBThe University of Birmingham757